Aurobindo Pharma receives USFDA approval for Tranexamic Acid Injection

18 Jan 2016 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Tranexamic Acid Injection, (100 mg/mL) 1000 mg/10 mL single-dose vial. This product is expected to be launched by the end of Q4 FY15-16. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Cyklokapron Injection, 100 mg/mL, of Pharmacia and Upjohn Company.

Tranexamic Acid Injection is used in the treatment of short-term control of bleeding in hemophiliacs, including dental extraction procedures. This product is in the WHOs list of essential medicines. The approved product has an estimated market size of $50 million for the twelve months ending November 2015 according to IMS.

This is the 22nd ANDA (including two tentative approval) approved out of Unit IV formulation facility in Hyderabad, India used for manufacturing general injectable products. Aurobindo now has a total of 232 ANDA approvals (201 Final approvals including 10 from Aurolife Pharma LLC and 31 Tentative approvals) from USFDA.



Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×